119 related articles for article (PubMed ID: 38059836)
1. Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
Gu H; Yan W; Yang J; Liu B; Zhao X; Wang H; Xu W; Wang C; Chen Y; Dong Q; Zhu Q; Xu Y; Zou Y
J Med Chem; 2024 Feb; 67(3):1932-1948. PubMed ID: 38059836
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors.
Gu H; Yan W; Wang Y; Xu W; Huang L; Yang J; Zhai B; Wang H; Su Y; Zhu Q; Liu B; Hao H; Zou Y; Xu Y
J Med Chem; 2023 Jan; 66(1):473-490. PubMed ID: 36576395
[TBL] [Abstract][Full Text] [Related]
3. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy.
Yang J; Liu B; Yan W; Zhao X; Wang C; Zhu Q; Zou Y; Xu Y; Gu H
Bioorg Chem; 2024 Jul; 148():107469. PubMed ID: 38781669
[TBL] [Abstract][Full Text] [Related]
4. Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.
Xu J; Zhao A; Chen D; Wang J; Ma J; Qing L; Li Y; Fang H; He H; Pan W; Zhang S
Eur J Med Chem; 2024 Feb; 266():116160. PubMed ID: 38277917
[TBL] [Abstract][Full Text] [Related]
5. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Gozgit JM; Vasbinder MM; Abo RP; Kunii K; Kuplast-Barr KG; Gui B; Lu AZ; Molina JR; Minissale E; Swinger KK; Wigle TJ; Blackwell DJ; Majer CR; Ren Y; Niepel M; Varsamis ZA; Nayak SP; Bamberg E; Mo JR; Church WD; Mady ASA; Song J; Utley L; Rao PE; Mitchison TJ; Kuntz KW; Richon VM; Keilhack H
Cancer Cell; 2021 Sep; 39(9):1214-1226.e10. PubMed ID: 34375612
[TBL] [Abstract][Full Text] [Related]
6. PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells.
Rasmussen M; Tan S; Somisetty VS; Hutin D; Olafsen NE; Moen A; Anonsen JH; Grant DM; Matthews J
Cells; 2021 Mar; 10(3):. PubMed ID: 33799807
[TBL] [Abstract][Full Text] [Related]
7. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of N-substituted indazole-3-carboxamides as poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors(†).
Patel MR; Pandya KG; Lau-Cam CA; Singh S; Pino MA; Billack B; Degenhardt K; Talele TT
Chem Biol Drug Des; 2012 Apr; 79(4):488-96. PubMed ID: 22177599
[TBL] [Abstract][Full Text] [Related]
11. [1,2,4]Triazolo[3,4-
Murthy S; Nizi MG; Maksimainen MM; Massari S; Alaviuhkola J; Lippok BE; Vagaggini C; Sowa ST; Galera-Prat A; Ashok Y; Venkannagari H; Prunskaite-Hyyryläinen R; Dreassi E; Lüscher B; Korn P; Tabarrini O; Lehtiö L
J Med Chem; 2023 Jan; 66(2):1301-1320. PubMed ID: 36598465
[TBL] [Abstract][Full Text] [Related]
12. A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor.
Chen H; Diolaiti ME; O'Leary PC; Rojc A; Krogan NJ; Kim M; Ashworth A
Mol Cancer Ther; 2022 Jul; 21(7):1076-1089. PubMed ID: 35439318
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
Scarpelli R; Boueres JK; Cerretani M; Ferrigno F; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
Bioorg Med Chem Lett; 2010 Jan; 20(2):488-92. PubMed ID: 20007017
[TBL] [Abstract][Full Text] [Related]
14. PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis.
Manetsch P; Böhi F; Nowak K; Leslie Pedrioli DM; Hottiger MO
Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2309047120. PubMed ID: 38011562
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2
Cheng Z; Wang Y; Zhang Y; Zhang C; Wang M; Wang W; He J; Wang Y; Zhang H; Zhang Q; Ding C; Wu D; Yang L; Liu M; Lu W
J Med Chem; 2023 May; 66(9):6218-6238. PubMed ID: 36880691
[TBL] [Abstract][Full Text] [Related]
16. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors.
Zhang S; Zhang Y; Wang Z; Qing L; Fu S; Xu J; Li Y; Fang H; He H
Eur J Med Chem; 2023 Dec; 261():115836. PubMed ID: 37826932
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
[TBL] [Abstract][Full Text] [Related]
18. Reduced Colonic Mucosal Injury in 2,3,7,8-Tetrachlorodibenzo-
Hutin D; Hagen KA; Shao P; Sugamori K; Grant DM; Matthews J
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055106
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
20. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Jones P; Wilcoxen K; Rowley M; Toniatti C
J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
